Bendahet 25 & 100 25 mg, 100 mg Powder for concentrate for solution for infusion
PDF Leaflet Revision Date: July 2021
Clinical Summary
Quick overview from the medicine insert
Indication
First-line treatment for specific hematological malignancies.
Dosage (summary)
100 mg/mu00b2 on days 1 and 2 for CLL; 90 mg/mu00b2 with rituximab for NHL; 120-150 mg/mu00b2 for multiple myeloma.
Onset of Action / Duration
Onset: 30 mins, Duration: 6-8 hours
Special Populations
- Elderly patients
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy and breastfeeding.
Key Drug Interactions
- CYP1A2 inhibitors
- Ciclosporin
- Tacrolimus
Contraindications
- Hypersensitivity
- Severe hepatic impairment
- Severe bone marrow suppression
- Pregnancy
- Lactation
Common side effects
- Leukopenia
- Thrombocytopenia
- Nausea
- Vomiting
- Skin reactions
Counselling Points
- Avoid pregnancy during treatment
- Monitor for signs of infection
- Report severe skin reactions immediately
Serious warnings
- Myelosuppression
- Infection risk
- Severe skin reactions
- Cardiac monitoring required
On This Page
Loading package insert…
Medinsert AI
Hello! I am Medinsert Ai. What would you like to know about this professional information leaftleft?
